GlassScriptPhysician profile
Angel M Johnson
NPI 1194005934
$63,137.02
in general payments reported to CMS, 2019-2025
60 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,123 · 2020: $922 · 2021: $14K · 2022: $12K · 2023: $15K · 2024: $5,626 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $5,152 · Travel and Lodging: $3,642 · Honoraria: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,820.00 |
| Food and Beverage | $5,152.45 |
| Travel and Lodging | $3,641.58 |
| Honoraria | $372.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $42,657.30 | 2020-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $10,901.96 | 2019-2025 | Axonics, Solyx Sis System |
| Coloplast Corp | $1,133.30 | 2019-2024 | |
| Medtronic, INC. | $1,090.64 | 2024-2025 | Altaviva, Interstim |
| Applied Medical Resources Corporation | $901.54 | 2022 | |
| Astellas Pharma US INC | $649.13 | 2019-2025 | Veozah, Myrbetriq |
| Dentsply Ih INC. | $406.83 | 2019-2022 | |
| 180 Medical, INC. | $403.67 | 2019-2025 | Gentlecath, Cure Catheter |
| Pfizer INC. | $373.92 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $367.53 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $294.93 | 2019-2025 | Erleada, Akeega |
| Dendreon Pharmaceuticals LLC | $271.41 | 2019-2022 | |
| Antares Pharma, INC. | $243.62 | 2019-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $221.39 | 2020-2025 | Keytruda |
| Tolmar, INC. | $201.28 | 2023-2025 | Eligard, Jatenzo |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.